Harrow Inc (NASDAQ:HROW) reported a 45% increase in total revenue for the third quarter compared to the same period in 2024, ...
Get key insights from Harrow’s Q3 2025 earnings: strong growth in ophthalmic meds, major VEVYE coverage wins, and updated financial outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback